XLRN
Income statement / Annual
Last year (2020), Acceleron Pharma Inc.'s total revenue was $92.52 M,
an increase of 25.04% from the previous year.
In 2020, Acceleron Pharma Inc.'s net income was -$166.03 M.
See Acceleron Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
Operating Revenue |
$92.52 M |
$73.99 M |
$13.99 M |
$13.48 M |
$27.77 M |
$18.10 M |
$14.63 M |
$57.23 M |
$15.25 M |
$80.91 M |
Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$92.52 M
|
$73.99 M
|
$13.99 M
|
$13.48 M
|
$27.77 M
|
$18.10 M
|
$14.63 M
|
$57.23 M
|
$15.25 M
|
$80.91 M
|
Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
Research and Development Expenses |
$173.92 M
|
$153.95 M
|
$103.90 M
|
$89.73 M
|
$68.58 M
|
$58.40 M
|
$50.90 M
|
$36.05 M
|
$35.32 M
|
$32.71 M
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$34.50 M
|
$33.74 M
|
$25.30 M
|
$20.57 M
|
$14.20 M
|
$14.23 M
|
$8.82 M
|
$8.14 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$0.00
|
$0.00
|
$34.50 M
|
$33.74 M
|
$25.30 M
|
$20.57 M
|
$14.20 M
|
$14.23 M
|
$8.82 M
|
$8.14 M
|
Other Expenses |
$85.91 M
|
$56.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$259.83 M
|
$210.44 M
|
$138.41 M
|
$123.46 M
|
$93.88 M
|
$78.98 M
|
$65.10 M
|
$50.28 M
|
$44.14 M
|
$40.86 M
|
Cost And Expenses |
$259.83 M
|
$210.44 M
|
$138.41 M
|
$123.46 M
|
$93.88 M
|
$78.98 M
|
$65.10 M
|
$50.28 M
|
$44.14 M
|
$42.36 M
|
Interest Income |
$2.87 M
|
$10.71 M
|
$5.57 M
|
$2.55 M
|
$1.85 M
|
$512,000.00
|
$83,000.00
|
$39,000.00
|
$91,000.00
|
$17,000.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$922,000.00
|
$2.09 M
|
$1.53 M
|
$1.82 M
|
Depreciation & Amortization |
$3.85 M
|
$3.94 M
|
$3.75 M
|
$2.83 M
|
$1.68 M
|
$1.18 M
|
$1.12 M
|
$915,000.00
|
$1.29 M
|
$3.13 M
|
EBITDA |
-$162.16 M |
-$120.98 M |
-$115.15 M |
-$105.60 M |
-$55.31 M |
-$62.72 M |
-$49.22 M |
-$18.89 M |
-$29.76 M |
$41.22 M |
EBITDA Ratio |
-1.75
|
-1.64
|
-8.23
|
-7.83
|
-1.99
|
-3.47
|
-3.36
|
-0.33
|
-1.95
|
0.51
|
Operating Income Ratio |
-1.81
|
-1.84
|
-8.89
|
-8.16
|
-2.38
|
-3.36
|
-3.45
|
0.12
|
-1.89
|
0.48
|
Total Other Income/Expenses Net |
$1.30 M
|
$11.53 M
|
$5.52 M
|
$1.56 M
|
$9.12 M
|
-$3.02 M
|
-$795,000.00
|
-$28.85 M
|
-$3.69 M
|
-$2.29 M
|
Income Before Tax |
-$166.01 M
|
-$124.92 M
|
-$118.90 M
|
-$108.42 M
|
-$56.99 M
|
-$63.89 M
|
-$51.26 M
|
-$21.90 M
|
-$32.58 M
|
$36.27 M
|
Income Before Tax Ratio |
-1.79
|
-1.69
|
-8.5
|
-8.04
|
-2.05
|
-3.53
|
-3.5
|
-0.38
|
-2.14
|
0.45
|
Income Tax Expense |
$21,000.00
|
-$62,000.00
|
-$27,000.00
|
$32,000.00
|
$24,000.00
|
-$3.02 M
|
$127,000.00
|
-$26.76 M
|
-$2.16 M
|
-$468,000.00
|
Net Income |
-$166.03 M
|
-$124.86 M
|
-$118.87 M
|
-$108.45 M
|
-$57.01 M
|
-$63.89 M
|
-$51.26 M
|
-$21.90 M
|
-$32.58 M
|
$36.27 M
|
Net Income Ratio |
-1.79
|
-1.69
|
-8.5
|
-8.04
|
-2.05
|
-3.53
|
-3.5
|
-0.38
|
-2.14
|
0.45
|
EPS |
-2.92 |
-2.38 |
-2.59 |
-2.68 |
-1.52 |
-1.92 |
-1.63 |
-1.04 |
-1.55 |
1.73 |
EPS Diluted |
-2.92 |
-2.38 |
-2.59 |
-2.68 |
-1.52 |
-1.92 |
-1.63 |
-1.04 |
-1.55 |
1.58 |
Weighted Average Shares Out |
$56.80 M
|
$52.45 M
|
$45.90 M
|
$40.42 M
|
$37.43 M
|
$33.30 M
|
$31.52 M
|
$21.06 M
|
$21.06 M
|
$20.95 M
|
Weighted Average Shares Out Diluted |
$56.80 M
|
$52.45 M
|
$45.90 M
|
$40.42 M
|
$37.43 M
|
$33.30 M
|
$31.52 M
|
$21.06 M
|
$21.06 M
|
$22.97 M
|
Link |
|
|
|
|
|
|
|
|
|
|